PMID- 37332787
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230620
IS  - 2470-1343 (Electronic)
IS  - 2470-1343 (Linking)
VI  - 8
IP  - 23
DP  - 2023 Jun 13
TI  - Core-Shell Nanostructured Drug Delivery Platform Based on Biocompatible 
      Metal-Organic Framework-Ligated Polyethyleneimine for Targeted Hepatocellular 
      Carcinoma Therapy.
PG  - 20779-20791
LID - 10.1021/acsomega.3c01385 [doi]
AB  - Multifunctional nanosized metal-organic frameworks (NMOFs) have advanced rapidly 
      over the past decade to develop drug delivery systems (DDSs). These material 
      systems still lack precise and selective cellular targeting, as well as the fast 
      release of the quantity of drugs that are simply adsorbed within and on the 
      external surface of nanocarriers, which hinders their application in the drug 
      delivery. Herein, we designed a biocompatible Zr-based NMOF with an engineered 
      core and the hepatic tumor-targeting ligand, glycyrrhetinic acid grafted to 
      polyethyleneimine (PEI) as the shell. The improved core-shell serves as a 
      superior nanoplatform for efficient controlled and active delivery of the 
      anticancer drug doxorubicin (DOX) against hepatic cancer cells (HepG2 cells). In 
      addition to their high loading capacity of 23%, the developed nanostructure 
      DOX@NMOF-PEI-GA showed an acidic pH-stimulated response and extended the drug 
      release time to 9 days as well as enhanced the selectivity toward the tumor 
      cells. Interestingly, the DOX-free nanostructures showed a minimal toxic effect 
      on both normal human skin fibroblast (HSF) and hepatic cancer cell line (HepG2), 
      but the DOX-loaded nanostructures exhibited a superior killing effect toward the 
      hepatic tumor, thus opening the way for the active drug delivery and achieving 
      efficient cancer therapy applications.
CI  - (c) 2023 The Authors. Published by American Chemical Society.
FAU - Fytory, Mostafa
AU  - Fytory M
AUID- ORCID: 0000-0001-8783-4515
AD  - Nanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and 
      Technology, 6 October City, 12578 Giza, Egypt.
AD  - Material Science and Nanotechnology Department, Faculty of Postgraduate Studies 
      for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt.
FAU - Mansour, Amira
AU  - Mansour A
AD  - Nanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and 
      Technology, 6 October City, 12578 Giza, Egypt.
FAU - El Rouby, Waleed M A
AU  - El Rouby WMA
AUID- ORCID: 0000-0003-0754-7562
AD  - Material Science and Nanotechnology Department, Faculty of Postgraduate Studies 
      for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt.
FAU - Farghali, Ahmed A
AU  - Farghali AA
AD  - Material Science and Nanotechnology Department, Faculty of Postgraduate Studies 
      for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt.
FAU - Zhang, Xiaorong
AU  - Zhang X
AD  - Molecular Bioanalytics and Bioelectronics Group, Institute of Biochemistry and 
      Biology, University of Potsdam, 14476 Potsdam-Golm, Germany.
FAU - Bier, Frank
AU  - Bier F
AD  - Molecular Bioanalytics and Bioelectronics Group, Institute of Biochemistry and 
      Biology, University of Potsdam, 14476 Potsdam-Golm, Germany.
FAU - Abdel-Hafiez, Mahmoud
AU  - Abdel-Hafiez M
AUID- ORCID: 0000-0002-1802-5279
AD  - Department of Physics and Astronomy, Uppsala University, Box 516, SE-75120 
      Uppsala, Sweden.
FAU - El-Sherbiny, Ibrahim M
AU  - El-Sherbiny IM
AUID- ORCID: 0000-0002-8179-437X
AD  - Nanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and 
      Technology, 6 October City, 12578 Giza, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20230531
PL  - United States
TA  - ACS Omega
JT  - ACS omega
JID - 101691658
PMC - PMC10269253
COIS- The authors declare no competing financial interest.
EDAT- 2023/06/19 06:41
MHDA- 2023/06/19 06:42
PMCR- 2023/05/31
CRDT- 2023/06/19 02:41
PHST- 2023/03/01 00:00 [received]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/06/19 06:42 [medline]
PHST- 2023/06/19 06:41 [pubmed]
PHST- 2023/06/19 02:41 [entrez]
PHST- 2023/05/31 00:00 [pmc-release]
AID - 10.1021/acsomega.3c01385 [doi]
PST - epublish
SO  - ACS Omega. 2023 May 31;8(23):20779-20791. doi: 10.1021/acsomega.3c01385. 
      eCollection 2023 Jun 13.